#WeMakeDNA - 用于传染性疾病研究的合成生物学

2020 年日本分子生物学学会年度会议

alt text
演讲者
Nobuyoshi Akimitsu
东京大学同位素科学中心研发部教授
Takeshi Kawai
Twist Bioscience 合成生物学/药物研发部门,业务发展经理

本次网络研讨会中涵盖的内容
Akimitsu 博士将展示哺乳动物细胞中 RNA 降解产生的分子碱基及其应用。
了解 Twist 的 COVID-19 相关产品,例如抗-SARS-CoV2-抗体。
Kawai 博士还将介绍 Twist 基因突变文库平台,例如精准多样性散点突变基因文库 (SOLD)
您也可进一步了解 Twist 的 SOLD 文库。

Twist Bioscience hosted a live Biotechnology Seminar (Webinar) during lunchtime as part of the Annual Meeting of the Molecular Biology Society of Japan.

RNA degradation contributes to the regulation of gene expression and RNA quality control. Dr. Akimitsu will show the molecular bases of RNA degradation in mammalian cells. In addition, he will introduce the application of RNA degradation/stabilization to nucleic acid medicine. In this regard, he has developed Fate-seq, a NGS technique based on the silicon-based massively parallel DNA synthesis platform. He will also give an example of application of Fate-seq for the SARS-CoV-2 study.

Twist Bioscience provides synthetic biology and genomics researchers with tools to accelerate their research at low cost with a silicon-based massively parallel DNA synthesis platform. In this talk, Dr. Kawai will introduce the product groups related to COVID-19 (synthetic RNA control, respiratory disease NGS panel, anti-SARS-CoV2-antibody, etc.). He will also introduce the Twist variant library platform such as the Spread-Out Low Diversity (SOLD) library, which is useful for molecular evolution and protein engineering.

填写您的详细信息,观看网络研讨会

 

 

Powered by Translations.com GlobalLink Web Software